BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1225 related articles for article (PubMed ID: 9223549)

  • 1. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
    Millan MJ; Newman-Tancredi A; Audinot V; Cussac D; Lejeune F; Nicolas JP; Cogé F; Galizzi JP; Boutin JA; Rivet JM; Dekeyne A; Gobert A
    Synapse; 2000 Feb; 35(2):79-95. PubMed ID: 10611634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.
    Millan MJ; Hjorth S; Samanin R; Schreiber R; Jaffard R; De Ladonchamps B; Veiga S; Goument B; Peglion JL; Spedding M; Brocco M
    J Pharmacol Exp Ther; 1997 Jul; 282(1):148-61. PubMed ID: 9223550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors.
    Gobert A; Millan MJ
    Neuropsychopharmacology; 1999 Aug; 21(2):268-84. PubMed ID: 10432475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
    Gobert A; Rivet JM; Lejeune F; Newman-Tancredi A; Adhumeau-Auclair A; Nicolas JP; Cistarelli L; Melon C; Millan MJ
    Synapse; 2000 Jun; 36(3):205-21. PubMed ID: 10819900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists.
    Millan MJ; Canton H; Gobert A; Lejeune F; Rivet JM; Bervoets K; Brocco M; Widdowson P; Mennini T; Audinot V
    J Pharmacol Exp Ther; 1994 Jan; 268(1):337-52. PubMed ID: 8301575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
    Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Adhumeau A; Brocco M; Nicolas JP; Boutin JA; Despaux N; Peglion JL
    J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis.
    Millan MJ; Gobert A; Roux S; Porsolt R; Meneses A; Carli M; Di Cara B; Jaffard R; Rivet JM; Lestage P; Mocaer E; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2004 Oct; 311(1):190-203. PubMed ID: 15146031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the activity of central serotoninergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats.
    Gobert A; Lejeune F; Rivet JM; Audinot V; Newman-Tancredi A; Millan MJ
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1032-46. PubMed ID: 7791073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats.
    Gobert A; Rivet JM; Cistarelli L; Melon C; Millan MJ
    J Neurochem; 1997 Dec; 69(6):2616-9. PubMed ID: 9375697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors.
    Gobert A; Billiras R; Cistarelli L; Millan MJ
    J Neurosci Methods; 2004 Dec; 140(1-2):141-52. PubMed ID: 15589344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
    Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
    J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat.
    Mignon L; Wolf WA
    Psychopharmacology (Berl); 2002 Aug; 163(1):85-94. PubMed ID: 12185404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535.
    Lejeune F; Millan MJ
    Synapse; 1998 Oct; 30(2):172-80. PubMed ID: 9723787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist.
    De Vry J; Schohe-Loop R; Heine HG; Greuel JM; Mauler F; Schmidt B; Sommermeyer H; Glaser T
    J Pharmacol Exp Ther; 1998 Mar; 284(3):1082-94. PubMed ID: 9495870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
    Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
    J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine.
    Millan MJ; Lejeune F; Gobert A; Brocco M; Auclair A; Bosc C; Rivet JM; Lacoste JM; Cordi A; Dekeyne A
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1206-22. PubMed ID: 11082458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.